InnoSer expands its operations to Belgium
From December 1st onwards InnoSer will be operational in Belgium. By its presence, we want to accommodate the increasing demand for preclinical research expertise and infrastructure in Belgium as well as strengthening our position on the European market.
Job opportunities at InnoSer
Currently there are two job opportunities at InnoSer. As a Contract Research Organisation (CRO) acting in the preclinical phase in several therapeutic fields, we offer highly sophisticated transgenic services. Due to the expansion of our activities into Belgium and to accelerate growth, we are looking for (commercial) talent to strengthen our young team and broaden our network.
We have an open position for a Business Development Manager (BDM) as from 1 January 2018. There's also a position for a veterinarian.
Pkd: a unique in vivo mouse assay
At InnoSer we deliver an in vivo mouse assay facilitating drug discovery for Autosomal Dominant Polycystic Kidney Disease (ADPKD). ADPKD is a genetic kidney disease, with a prevalence of 4 to 10.000.
In 85% the Pkd1-gene is mutated, in 15% the Pkd2-gene is mutated. The Pkd1-gene encodes the protein polycystin-1 and the Pkd2-gene encodes polycystin-2. The kidney is the organ affected the most. Thousands of fluid filled cysts pile up in the kidney during human life. Fluid filled cysts can not only be present in the kidneys in ADPKD patients, but have been reported in liver and pancreas as well. Other known complications in ADPKD patients are for instance hypertension and cardiovascular disease.
Rapidly screen for ADPKD treatments
Kidney cysts develop amongst others due to a mutated Pkd1-gene in the kidney epithelial cells. The formation of cysts can be mimicked by a Tamoxifen inducible knockout disease model in mice.
InnoSer joins TRANSMED programme
TRANSMED brings together four academic groups with four non-academic and SME partners and four associated partners. The academic groups are EKUT, UNIMORE, ULUND and HI, the non-academic and SME partners are SPPD, INCU, Oculis and InnoSer. The four associated partners are 2BBB, BIOLOG, NLO and HCTC.
Each partner will provide specific critical expertise, which allows TRANSMED to present a training plan that covers all major aspects of translational research:
• Basic research into disease mechanisms and target definition;
• drug design and development;
• in vitro test systems and in vivo disease models;
• drug delivery systems;
• good manufacturing practice;
• toxicological testing and pharmacokinetics;
• regulatory affairs;
• intellectual property;
• all the way to clinical trials and commercialisation.